Is Paxlovid Any Better Than Placebo for Long COVID?
(MedPage Today) -- Nirmatrelvir-ritonavir (Paxlovid) wasn't any more effective at relieving long COVID symptoms than placebo, according to a large double-blind phase II trial. At 90 days in RECOVER-VITAL, symptoms meaningfully improved among the...
DeafMonitor aggregates Deaf-community news and credits every story to its original publisher. This story was reported by MedPage Today — ENT.
Read the full story at MedPage Today — ENT
Read the full story at MedPage Today — ENT